;PMID: 11560869
;source_file_2662.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..145] = [t:49..145]
;2)section:[e:149..215] = [t:149..215]
;3)section:[e:219..320] = [t:219..320]
;4)sentence:[e:324..437] = [t:324..437]
;5)sentence:[e:438..716] = [t:438..716]
;6)sentence:[e:718..810] = [t:718..810]
;7)sentence:[e:811..940] = [t:811..940]
;8)sentence:[e:941..1106] = [t:941..1106]
;9)sentence:[e:1107..1267] = [t:1107..1267]
;10)sentence:[e:1269..1525] = [t:1269..1525]
;11)sentence:[e:1526..1643] = [t:1526..1643]
;12)sentence:[e:1644..1756] = [t:1644..1756]
;13)sentence:[e:1757..1947] = [t:1757..1947]
;14)sentence:[e:1948..2075] = [t:1948..2075]
;15)sentence:[e:2076..2165] = [t:2076..2165]
;16)section:[e:2169..2214] = [t:2169..2214]

;section 0 Span:0..43
;Drug Metab Dispos. 2001 Oct;29(10):1269-76.
(SEC
  (FRAG (NNP:[0..4] Drug) (NNP:[5..10] Metab) (NNP:[11..17] Dispos)
        (.:[17..18] .) (CD:[19..23] 2001) (CC:[24..31] Oct;29-LRB-)
        (CD:[31..33] 10) (NN:[33..34] -RRB-) (::[34..35] :) (CD:[35..39] 1269)
        (::[39..40] -) (CD:[40..42] 76) (.:[42..43] .)))

;sentence 1 Span:49..145
;In vitro metabolism of tegaserod in human liver and intestine: assessment of 
;drug interactions.
;[72..81]:substance:"tegaserod"
;[127..131]:substance:"drug"
(SENT
  (NP-HLN
    (NP
      (NP
        (ADJP (FW:[49..51] In) (FW:[52..57] vitro))
        (NN:[58..68] metabolism))
      (PP (IN:[69..71] of)
        (NP (NN:[72..81] tegaserod)))
      (PP-LOC (IN:[82..84] in)
        (NP
          (NP
            (NML-1 (JJ:[85..90] human))
            (NN:[91..96] liver))
          (CC:[97..100] and)
          (NP
            (NML-1 (-NONE-:[100..100] *P*))
            (NN:[101..110] intestine)))))
    (::[110..111] :)
    (NP
      (NP (NN:[112..122] assessment))
      (PP (IN:[123..125] of)
        (NP (NN:[127..131] drug) (NNS:[132..144] interactions))))
    (.:[144..145] .)))

;section 2 Span:149..215
;Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V.
(SEC
  (FRAG (NNP:[149..156] Vickers) (NNP:[157..159] AE) (,:[159..160] ,)
        (NNP:[161..170] Zollinger) (NNP:[171..173] M,)
        (NNP:[174..183] Dannecker) (NNP:[184..185] R) (,:[185..186] ,)
        (NNP:[187..192] Tynes) (NNP:[193..194] R) (,:[194..195] ,)
        (NNP:[196..201] Heitz) (NNP:[202..203] F) (,:[203..204] ,)
        (NNP:[205..212] Fischer) (NNP:[213..214] V) (.:[214..215] .)))

;section 3 Span:219..320
;Preclinical Safety, Novartis Institute for Biomedical Research, East Hanover,
; New Jersey 07936, USA.
(SEC
  (FRAG (NNP:[219..230] Preclinical) (NNP:[231..237] Safety) (,:[237..238] ,)
        (NNP:[239..247] Novartis) (NNP:[248..257] Institute) (IN:[258..261] for)
        (NNP:[262..272] Biomedical) (NNP:[273..281] Research) (,:[281..282] ,)
        (NNP:[283..287] East) (NNP:[288..295] Hanover) (,:[295..296] ,)
        (NNP:[298..301] New) (NNP:[302..308] Jersey) (CD:[309..314] 07936)
        (,:[314..315] ,) (NNP:[316..319] USA) (.:[319..320] .)))

;sentence 4 Span:324..437
;Tegaserod is a selective 5-HT(4) receptor partial agonist with promotile 
;activity in the gastrointestinal tract.
;[324..333]:substance:"Tegaserod"
;[349..365]:substance:"5-HT(4) receptor"
;[374..381]:substance:"agonist"
(SENT
  (S
    (NP-SBJ (NN:[324..333] Tegaserod))
    (VP (VBZ:[334..336] is)
      (NP-PRD
        (NP (DT:[337..338] a) (JJ:[339..348] selective)
          (NML (NN:[349..356] 5-HT-LRB-4-RRB-) (NN:[357..365] receptor))
          (JJ:[366..373] partial) (NN:[374..381] agonist))
        (PP (IN:[382..386] with)
          (NP
            (NP (NN:[387..396] promotile) (NN:[398..406] activity))
            (PP-LOC (IN:[407..409] in)
              (NP (DT:[410..413] the) (JJ:[414..430] gastrointestinal)
                  (NN:[431..436] tract)))))))
    (.:[436..437] .)))

;sentence 5 Span:438..716
;This study was designed to describe the  metabolic pathways of tegaserod in
;the human liver and small intestine in vitro,  to identify the enzymes
;involved in tegaserod metabolism, and to investigate the  effect of tegaserod
;on CYP-catalyzed reactions involving other compounds.
;[501..510]:substance:"tegaserod"
;[577..584]:substance:"enzymes"
;[597..606]:substance:"tegaserod"
;[653..662]:substance:"tegaserod"
;[666..669]:cyp450:"CYP"
;[706..715]:substance:"compounds"
(SENT
  (S
    (NP-SBJ-2 (DT:[438..442] This) (NN:[443..448] study))
    (VP (VBD:[449..452] was)
      (VP (VBN:[453..461] designed)
        (S
          (NP-SBJ-2 (-NONE-:[461..461] *))
          (VP
            (VP (TO:[462..464] to)
              (VP (VB:[465..473] describe)
                (NP
                  (NP (DT:[474..477] the) (JJ:[479..488] metabolic)
                      (NNS:[489..497] pathways))
                  (PP (IN:[498..500] of)
                    (NP (NN:[501..510] tegaserod))))
                (PP-LOC (IN:[511..513] in)
                  (NP (DT:[514..517] the)
                    (NML
                      (NML
                        (ADJP-1 (JJ:[518..523] human))
                        (NN:[524..529] liver))
                      (CC:[530..533] and)
                      (NML
                        (ADJP-1 (-NONE-:[533..533] *P*))
                        (JJ:[534..539] small) (NN:[540..549] intestine)))))
                (ADVP (FW:[550..552] in) (FW:[553..558] vitro))))
            (,:[558..559] ,)
            (VP (TO:[561..563] to)
              (VP (VB:[564..572] identify)
                (NP
                  (NP (DT:[573..576] the) (NNS:[577..584] enzymes))
                  (VP (VBN:[585..593] involved)
                    (NP (-NONE-:[593..593] *))
                    (PP-LOC (IN:[594..596] in)
                      (NP (NN:[597..606] tegaserod) (NN:[607..617] metabolism)))))))
            (,:[617..618] ,) (CC:[619..622] and)
            (VP (TO:[623..625] to)
              (VP (VB:[626..637] investigate)
                (NP
                  (NP (DT:[638..641] the) (NN:[643..649] effect))
                  (PP (IN:[650..652] of)
                    (NP (NN:[653..662] tegaserod)))
                  (PP (IN:[663..665] on)
                    (NP
                      (NP
                        (ADJP (NN:[666..669] CYP) (HYPH:[669..670] -)
                              (VBN:[670..679] catalyzed))
                        (NNS:[680..689] reactions))
                      (VP (VBG:[690..699] involving)
                        (PP (JJ:[700..705] other)
                          (NP (NNS:[706..715] compounds)))))))))))))
    (.:[715..716] .)))

;sentence 6 Span:718..810
;Tegaserod was metabolized in human liver microsomes to O-desmethyl tegaserod
;at  a low rate.
;[718..727]:substance:"Tegaserod"
;[773..794]:substance:"O-desmethyl tegaserod"
(SENT
  (S
    (NP-SBJ-1 (NN:[718..727] Tegaserod))
    (VP (VBD:[728..731] was)
      (VP (VBN:[732..743] metabolized)
        (NP-1 (-NONE-:[743..743] *))
        (PP-LOC (IN:[744..746] in)
          (NP (JJ:[747..752] human) (NN:[753..758] liver)
              (NNS:[759..769] microsomes)))
        (PP (TO:[770..772] to)
          (NP (NN:[773..784] O-desmethyl) (NN:[785..794] tegaserod)))
        (PP (IN:[795..797] at)
          (NP (DT:[799..800] a) (JJ:[801..804] low) (NN:[805..809] rate)))))
    (.:[809..810] .)))

;sentence 7 Span:811..940
;This metabolite was also formed by cDNA expressed CYP2D6, and the  reaction
;in human liver microsomes was inhibited by quinidine.
;[816..826]:substance:"metabolite"
;[846..850]:substance:"cDNA"
;[861..867]:cyp450:"CYP2D6"
;[930..939]:substance:"quinidine"
(SENT
  (S
    (S
      (NP-SBJ-2 (DT:[811..815] This) (NN:[816..826] metabolite))
      (VP (VBD:[827..830] was)
        (ADVP (RB:[831..835] also))
        (VP (VBN:[836..842] formed)
          (NP-2 (-NONE-:[842..842] *))
          (PP (IN:[843..845] by)
            (NP-LGS
              (ADJP (NN:[846..850] cDNA) (VBN:[851..860] expressed))
              (NN:[861..867] CYP2D6))))))
    (,:[867..868] ,) (CC:[869..872] and)
    (S
      (NP-SBJ-1
        (NP (DT:[873..876] the) (NN:[878..886] reaction))
        (PP-LOC (IN:[887..889] in)
          (NP (JJ:[890..895] human) (NN:[896..901] liver)
              (NNS:[902..912] microsomes))))
      (VP (VBD:[913..916] was)
        (VP (VBN:[917..926] inhibited)
          (NP-1 (-NONE-:[926..926] *))
          (PP (IN:[927..929] by)
            (NP-LGS (NN:[930..939] quinidine))))))
    (.:[939..940] .)))

;sentence 8 Span:941..1106
;In human liver  slices, direct N-glucuronidation of tegaserod at the
;guanidine nitrogens (M43.2,  M43.8, and M45.3) was found, with M43.8 being
;the major metabolite.
;[993..1002]:substance:"tegaserod"
;[1010..1029]:substance:"guanidine nitrogens"
;[1031..1036]:substance:"M43.2"
;[1039..1044]:substance:"M43.8"
;[1050..1055]:substance:"M45.3"
;[1073..1078]:substance:"M43.8"
;[1095..1105]:substance:"metabolite"
(SENT
  (S
    (PP-LOC (IN:[941..943] In)
      (NP (JJ:[944..949] human) (NN:[950..955] liver) (NNS:[957..963] slices)))
    (,:[963..964] ,)
    (NP-SBJ-1
      (NP (JJ:[965..971] direct) (NN:[972..989] N-glucuronidation))
      (PP (IN:[990..992] of)
        (NP (NN:[993..1002] tegaserod)))
      (PP-LOC (IN:[1003..1005] at)
        (NP
          (NP (DT:[1006..1009] the)
             (NN:[1010..1019] guanidine) (NNS:[1020..1029] nitrogens))
          (NP (-LRB-:[1030..1031] -LRB-) (NN:[1031..1036] M43.2)
              (,:[1036..1037] ,) (NN:[1039..1044] M43.8) (,:[1044..1045] ,)
              (CC:[1046..1049] and) (NN:[1050..1055] M45.3)
              (-RRB-:[1055..1056] -RRB-)))))
    (VP (VBD:[1057..1060] was)
      (VP (VBN:[1061..1066] found)
        (NP-1 (-NONE-:[1066..1066] *))
        (,:[1066..1067] ,)
        (PP (IN:[1068..1072] with)
          (NP
            (NP (NN:[1073..1078] M43.8))
            (VP (VBG:[1079..1084] being)
              (NP (DT:[1085..1088] the) (JJ:[1089..1094] major)
                  (NN:[1095..1105] metabolite)))))))
    (.:[1105..1106] .)))

;sentence 9 Span:1107..1267
;Human small  intestine slices also metabolized tegaserod to the
;N-glucuronides, suggesting a  contribution of the small intestine to the
;presystemic metabolism.
;[1171..1185]:substance:"N-glucuronides"
(SENT
  (S
    (NP-SBJ
      (NML (JJ:[1107..1112] Human) (JJ:[1113..1118] small)
           (NN:[1120..1129] intestine))
      (NNS:[1130..1136] slices))
    (ADVP (RB:[1137..1141] also))
    (VP (VBD:[1142..1153] metabolized)
      (NP (NN:[1154..1163] tegaserod))
      (PP (TO:[1164..1166] to)
        (NP (DT:[1167..1170] the) (NNS:[1171..1185] N-glucuronides)))
      (,:[1185..1186] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1186..1186] *))
        (VP (VBG:[1187..1197] suggesting)
          (NP
            (NP (DT:[1198..1199] a) (NN:[1201..1213] contribution))
            (PP (IN:[1214..1216] of)
              (NP (DT:[1217..1220] the) (JJ:[1221..1226] small)
                  (NN:[1227..1236] intestine)))
            (PP (TO:[1237..1239] to)
              (NP (DT:[1240..1243] the) (JJ:[1244..1255] presystemic)
                  (NN:[1256..1266] metabolism)))))))
    (.:[1266..1267] .)))

;sentence 10 Span:1269..1525
;5-Methoxyindole-3-carboxylic acid (M29.0), the main metabolite in human
;plasma,  was generated in vitro by a sequence of reactions starting with
;nonenzymatic  acid-catalyzed hydrolysis, followed by enzymatic oxidation and
;conjugation with  glucuronic acid.
;[1269..1302]:substance:"5-Methoxyindole-3-carboxylic acid"
;[1304..1309]:substance:"M29.0"
;[1321..1331]:substance:"metabolite"
;[1428..1432]:substance:"acid"
;[1509..1524]:substance:"glucuronic acid"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (JJ:[1269..1297] 5-Methoxyindole-3-carboxylic)
            (NN:[1298..1302] acid))
        (NP (-LRB-:[1303..1304] -LRB-) (NN:[1304..1309] M29.0)
            (-RRB-:[1309..1310] -RRB-)))
      (,:[1310..1311] ,)
      (NP
        (NP (DT:[1312..1315] the) (JJ:[1316..1320] main)
            (NN:[1321..1331] metabolite))
        (PP-LOC (IN:[1332..1334] in)
          (NP (JJ:[1335..1340] human) (NN:[1341..1347] plasma)))))
    (,:[1347..1348] ,)
    (VP (VBD:[1350..1353] was)
      (VP (VBN:[1354..1363] generated)
        (NP-1 (-NONE-:[1363..1363] *))
        (ADVP (FW:[1364..1366] in) (FW:[1367..1372] vitro))
        (PP (IN:[1373..1375] by)
          (NP-LGS
            (NP (DT:[1376..1377] a) (NN:[1378..1386] sequence))
            (PP (IN:[1387..1389] of)
              (NP (NNS:[1390..1399] reactions)))
            (VP (VBG:[1400..1408] starting)
              (PP (IN:[1409..1413] with)
                (NP
                  (NP (JJ:[1414..1426] nonenzymatic)
                    (ADJP (NN:[1428..1432] acid) (HYPH:[1432..1433] -)
                          (VBN:[1433..1442] catalyzed))
                    (NN:[1443..1453] hydrolysis))
                  (,:[1453..1454] ,)
                  (VP (VBN:[1455..1463] followed)
                    (NP (-NONE-:[1463..1463] *))
                    (PP (IN:[1464..1466] by)
                      (NP-LGS
                        (NP (JJ:[1467..1476] enzymatic)
                            (NN:[1477..1486] oxidation))
                        (CC:[1487..1490] and)
                        (NP
                          (NP (NN:[1491..1502] conjugation))
                          (PP (IN:[1503..1507] with)
                            (NP (JJ:[1509..1519] glucuronic)
                                (NN:[1520..1524] acid))))))))))))))
    (.:[1524..1525] .)))

;sentence 11 Span:1526..1643
;Tegaserod inhibited CYP2C8, CYP2C9, CYP2C19, CYP2E1, and CYP3A  only to a
;small extent with IC(50) values >30 microM.
;[1526..1535]:substance:"Tegaserod"
;[1546..1552]:cyp450:"CYP2C8"
;[1554..1560]:cyp450:"CYP2C9"
;[1562..1569]:cyp450:"CYP2C19"
;[1571..1577]:cyp450:"CYP2E1"
;[1583..1588]:cyp450:"CYP3A"
;[1618..1624]:quantitative-name:"IC(50)"
;[1632..1635]:quantitative-value:">30"
;[1636..1642]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ (NN:[1526..1535] Tegaserod))
    (VP (VBD:[1536..1545] inhibited)
      (NP (NN:[1546..1552] CYP2C8) (,:[1552..1553] ,) (NN:[1554..1560] CYP2C9)
          (,:[1560..1561] ,) (NN:[1562..1569] CYP2C19) (,:[1569..1570] ,)
          (NN:[1571..1577] CYP2E1) (,:[1577..1578] ,) (CC:[1579..1582] and)
          (NN:[1583..1588] CYP3A))
      (PP-EXT (RB:[1590..1594] only) (TO:[1595..1597] to)
        (NP
          (NP (DT:[1598..1599] a) (JJ:[1600..1605] small)
              (NN:[1606..1612] extent))
          (PP (IN:[1613..1617] with)
            (NP
              (NP (NN:[1618..1624] IC-LRB-50-RRB-) (NNS:[1625..1631] values))
              (VP (SYM:[1632..1633] >)
                (NP (CD:[1633..1635] 30) (NN:[1636..1642] microM))))))))
    (.:[1642..1643] .)))

;sentence 12 Span:1644..1756
;Tegaserod more effectively  inhibited CYP1A2 and CYP2D6 with K(i) values of
;0.84 and 0.85 microM,  respectively.
;[1644..1653]:substance:"Tegaserod"
;[1682..1688]:cyp450:"CYP1A2"
;[1693..1699]:cyp450:"CYP2D6"
;[1705..1709]:quantitative-name:"K(i)"
;[1720..1724]:quantitative-value:"0.84"
;[1729..1733]:quantitative-value:"0.85"
;[1734..1740]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ (NN:[1644..1653] Tegaserod))
    (ADVP-MNR (RBR:[1654..1658] more) (RB:[1659..1670] effectively))
    (VP (VBD:[1672..1681] inhibited)
      (NP (NN:[1682..1688] CYP1A2) (CC:[1689..1692] and)
          (NN:[1693..1699] CYP2D6))
      (PP (IN:[1700..1704] with)
        (NP
          (NP (NN:[1705..1709] K-LRB-i-RRB-) (NNS:[1710..1716] values))
          (PP (IN:[1717..1719] of)
            (NP
              (NP (CD:[1720..1724] 0.84)
                (NML-1 (-NONE-:[1724..1724] *P*)))
              (CC:[1725..1728] and)
              (NP (CD:[1729..1733] 0.85)
                (NML-1 (NN:[1734..1740] microM)))))
          (,:[1740..1741] ,)
          (ADVP (RB:[1743..1755] respectively)))))
    (.:[1755..1756] .)))

;sentence 13 Span:1757..1947
;However, these K(i) values are approximately 140-fold greater than  the
;maximal tegaserod plasma concentrations following the clinically relevant 
;6-mg oral dose given to healthy volunteers.
;[1772..1776]:quantitative-name:"K(i)"
;[1802..1823]:quantitative-value:"140-fold greater than"
;[1837..1846]:substance:"tegaserod"
;[1904..1905]:quantitative-value:"6"
;[1906..1908]:quantitative-units:"mg"
(SENT
  (S
    (ADVP (RB:[1757..1764] However))
    (,:[1764..1765] ,)
    (NP-SBJ-1 (DT:[1766..1771] these) (NN:[1772..1776] K-LRB-i-RRB-)
              (NNS:[1777..1783] values))
    (VP (VBP:[1784..1787] are)
      (ADJP-PRD
        (ADJP
          (ADVP-EXT
            (QP (RB:[1788..1801] approximately) (CD:[1802..1805] 140))
            (HYPH:[1805..1806] -) (RB:[1806..1810] fold))
          (JJR:[1811..1818] greater))
        (PP (IN:[1819..1823] than)
          (NP (DT:[1825..1828] the) (JJ:[1829..1836] maximal)
              (NN:[1837..1846] tegaserod) (NN:[1847..1853] plasma)
              (NNS:[1854..1868] concentrations))))
      (S-ADV
        (NP-SBJ-1 (-NONE-:[1868..1868] *))
        (VP (VBG:[1869..1878] following)
          (NP
            (NP (DT:[1879..1882] the)
              (ADJP (RB:[1883..1893] clinically) (JJ:[1894..1902] relevant))
              (NML (CD:[1904..1905] 6) (HYPH:[1905..1906] -)
                   (NN:[1906..1908] mg))
              (JJ:[1909..1913] oral) (NN:[1914..1918] dose))
            (VP (VBN:[1919..1924] given)
              (NP (-NONE-:[1924..1924] *))
              (PP (TO:[1925..1927] to)
                (NP (JJ:[1928..1935] healthy) (NNS:[1936..1946] volunteers))))))))
    (.:[1946..1947] .)))

;sentence 14 Span:1948..2075
;M29.0, the main circulating  metabolite, did not demonstrate any inhibitory
;potential toward cytochrome P450  enzymes in vitro.
;[1948..1953]:substance:"M29.0"
;[1977..1987]:substance:"metabolite"
;[2041..2065]:cyp450:"cytochrome P450  enzymes"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1948..1953] M29.0))
      (,:[1953..1954] ,)
      (NP (DT:[1955..1958] the) (JJ:[1959..1963] main)
          (VBG:[1964..1975] circulating) (NN:[1977..1987] metabolite)))
    (,:[1987..1988] ,)
    (VP (VBD:[1989..1992] did) (RB:[1993..1996] not)
      (VP (VB:[1997..2008] demonstrate)
        (NP
          (NP (DT:[2009..2012] any) (JJ:[2013..2023] inhibitory)
              (NN:[2024..2033] potential))
          (PP (IN:[2034..2040] toward)
            (NP
              (NML (NN:[2041..2051] cytochrome) (NN:[2052..2056] P450))
              (NNS:[2058..2065] enzymes))))
        (ADVP (FW:[2066..2068] in) (FW:[2069..2074] vitro))))
    (.:[2074..2075] .)))

;sentence 15 Span:2076..2165
;Therefore, clinically relevant metabolic drug interactions  with tegaserod
;seem unlikely.
;[2117..2121]:substance:"drug"
;[2141..2150]:substance:"tegaserod"
(SENT
  (S
    (ADVP (RB:[2076..2085] Therefore))
    (,:[2085..2086] ,)
    (NP-SBJ
      (NP
        (ADJP (RB:[2087..2097] clinically) (JJ:[2098..2106] relevant))
        (JJ:[2107..2116] metabolic) (NN:[2117..2121] drug)
         (NNS:[2122..2134] interactions))
      (PP (IN:[2136..2140] with)
        (NP (NN:[2141..2150] tegaserod))))
    (VP (VBP:[2151..2155] seem)
      (ADJP-PRD (JJ:[2156..2164] unlikely)))
    (.:[2164..2165] .)))

;section 16 Span:2169..2214
;PMID: 11560869 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2169..2173] PMID) (::[2173..2174] :) (CD:[2175..2183] 11560869)
        (NN:[2184..2185] -LSB-) (NNP:[2185..2191] PubMed) (::[2192..2193] -)
        (NN:[2194..2201] indexed) (IN:[2202..2205] for)
        (NNP:[2206..2214] MEDLINE-RSB-)))
